USPH241220C90000
- 4.90
- 0.000.00%
US Physical Therapy Newsroom
US Physical Therapy Is Maintained at Outperform by Barrington Research
US Physical Therapy Analyst Ratings
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Maintains Target Price $108
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Maintains Target Price $108
US Physical Therapy Analyst Ratings
BofA Securities Maintains US Physical Therapy(USPH.US) With Hold Rating
US Physical Therapy Analyst Ratings
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Maintains Target Price $108
BofA Securities Maintains US Physical Therapy(USPH.US) With Hold Rating, Maintains Target Price $90
William Blair Initiates US Physical Therapy(USPH.US) With Hold Rating
US Physical Therapy Cut to Neutral From Buy by B of A Securities
BofA Securities Downgrades US Physical Therapy(USPH.US) to Hold Rating, Cuts Target Price to $90
US Physical Therapy Is Maintained at Outperform by Barrington Research
US Physical Therapy Analyst Ratings
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Maintains Target Price $108
US Physical Therapy Analyst Ratings
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Cuts Target Price to $108
BofA Securities Maintains US Physical Therapy(USPH.US) With Buy Rating, Cuts Target Price to $114
Maintaining 'Buy' Rating on US Physical Therapy Amid Cost Pressures and Revenue Growth
Analysts' Top Healthcare Picks: US Physical Therapy (USPH), Exact Sciences (EXAS)